Kendall E. Donaldson, MD

The series concludes with guidance on adopting emerging therapies, managing patient expectations, and addressing unmet needs in dry eye care.

Strategies for tapering and sustaining therapy once stabilization is achieved are discussed.

The importance of combining clinical metrics and patient-reported outcomes is examined.

They evaluate key efficacy data and patient outcomes from the COMET-2 and COMET-3 clinical trials.

The team reviews acoltremon’s mechanism in promoting basal tear production and maintaining ocular surface health.

Panelists discuss new DED treatments like Miebo and Vevye and how they integrate into treatment algorithms.

Experts highlight management nuances in patients with neuropathic pain, post–refractive surgery complications, or contact lens intolerance.

The panel addresses common patient frustrations and therapeutic limitations in today’s dry eye landscape.

Panelists share how they tailor therapy based on patient characteristics, symptoms, and clinical findings.

The discussion explores how basal and reflex tears differ and why composition impacts sustained eye comfort.

Experts explain how differentiating these subtypes guides treatment choices and outcomes.

Donaldson introduces the panel and outlines the series’ focus on improving dry eye management through tear function optimization.

Donaldson introduces the panel and outlines the series’ focus on improving dry eye management through tear function optimization.